Sign in

IMNN on Nasdaq

Imunon, Inc.

Imunon, Inc. is an American pharmaceutical preparations company based in Lawrenceville.1 Its shares trade on Nasdaq under the symbol IMNN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Catabasis Pharmaceuticals, DiaMedica Therapeutics Inc. or EXICURE, INC., or pick any stock.

  • TickerIMNN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLawrenceville, New Jersey1
  • Incorporated inDE2
  • Business address997 Lenox Drive, Suite 100, Lawrenceville, Nj 086482
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Market; and those listed under “Risk Factors” below and elsewhere in this Annual Report.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-4984.3%Operating margin5
-7179.6%Net margin5
0.0%Revenue growth, 20225
-122.4%Return on equity6
0.20×Debt to equity7
-$23.4MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development64¢$11.7M
  • Interest27¢$5.0M
  • Income tax9¢$1.6M

Out of $500.0K in revenue.5 The company lost money this year.

Financial statements

Revenue8975$500.0K in 2022+0% since 2019
0$200.0K$400.0K$600.0K2019: $500.0K$500.0K20192020: $500.0K$500.0K2020+0%2021: $500.0K$500.0K2021+0%2022: $500.0K$500.0K2022+0%
Operating income8975-$24.9M in 2022+21% since 2019
-$30.0M-$20.0M-$10.0M02019: -$20.6M-$20.6M20192020: -$18.5M-$18.5M2020−10%2021: -$21.0M-$21.0M2021+14%2022: -$24.9M-$24.9M2022+19%
Net income8975-$35.9M in 2022+113% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$16.9M-$16.9M20192020: -$21.5M-$21.5M2020+27%2021: -$20.8M-$20.8M2021−3%2022: -$35.9M-$35.9M2022+73%

Every line of the income statement as filed: the last 2 fiscal years, latest first.12

Period ending2025-12-312024-12-31
Research and development$7.8M$11.6M
General and administrative$6.9M$7.5M
Total operating expenses$14.7M$19.1M
Loss from operations-$14.7M-$19.1M
Investment income, net$155.7K$512.2K
Total other income, net$155.7K$512.2K
Net loss-$14.5M-$18.6M
Net loss per common share - basic-$6.83-$16.94
Net loss per common share - diluted-$6.83-$16.94
Weighted average common shares outstanding - basic2.1M shares1.1M shares
Weighted average common shares outstanding - diluted2.1M shares1.1M shares

Compare Imunon, Inc. with another company

Corporate structure

Imunon, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Imunon, Inc.

  • Imunon, Inc. Lawrenceville, New Jersey
    • CLSN Laboratories, Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Imunon, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.8M12 Dec 31, 2025$1.7M12 Dec 31, 2024+3.9%
Accumulated depreciation$1.3M12 Dec 31, 2025$1.2M12 Dec 31, 2024+6.7%
Property and equipment, net$529.9K12 Dec 31, 2025$541.3K12 Dec 31, 2024−2.1%
Operating-lease assets (leased space)$984.4K12 Dec 31, 2025$1.1M12 Dec 31, 2024−11.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.8M12 Dec 31, 2025$5.9M12 Dec 31, 2024+49.5%

Properties, in its own words

We own no real property and have no plans to acquire any real property in the future.

Lawrenceville, NJ Lease - In August 2023, the Company renewed its Lawrenceville office lease for a 24-month agreement for 9,850 square feet with monthly rent payments of approximately $22,983 to $23,394. In April 2025, the Company renewed its Lawrenceville office lease until November 30, 2028 for 4,359 square feet (to be reduced to 4,011 following July 1, 2026) with monthly rent payments of approximately $10,361 to $10,863.

The rest of Item 2

Huntsville, AL Lease - In January 2023, the Company renewed its Huntsville facility lease for a 60-month lease agreement for 11,420 square feet with monthly rent payments of approximately $28,550 to $30,903.

We believe our existing facilities are suitable and adequate to conduct our business.

Following is a table of future payments and maturity of our operating lease liabilities as of December 31, 2025:

For the year ending December 31,

2026 · 488,822

2027 · 498,086

2028 · 149,896

Subtotal future lease payments · 1,136,804

Less imputed interest · (128,039

Total lease liabilities · 1,008,765

Weighted average remaining life · 2.4 years

Weighted average discount rate · 9.98

The discount rate used was the Company’s incremental borrowing rate, which is 9.98%, as the Company could not determine the rate implicit in the lease.

For 2025, operating lease expense was $521,457 and cash paid for operating leases included in operating cash flows was $519,296. For 2024, operating lease expense was $634,848 and cash paid for operating leases included in operating cash flows was $626,323. Amortization expense was approximately $407,000 and $478,000 for the years ended December 31, 2025 and 2024, respectively.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led Imunon, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lawrence S. Olanoff2006
  2. Michael H. Tardugno2007–2022
  3. Goff Corinne Le2022–2023
  4. Stacy Lindborg2024–now

Chair

  1. Michael H. Tardugno2016–now

President

  1. Lawrence S. Olanoff2006
  2. Michael H. Tardugno2007–2022
  3. Goff Corinne Le2022–2023
  4. Stacy Lindborg2024–now

Chief financial officer

  1. Anthony P. Deasey2006–2007
  2. David G. Gaiero2024
  3. Kimberly Bragg2025–2026
  4. Joshua Blacher2026–now

Chief operating officer

  1. Anthony P. Deasey2006–2007
2010201520202025
Board members and other officers (26)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • CLSN Laboratories, Inc. Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • CELSION CORPNov 21, 2007 to Sep 19, 20222
  • CHEUNG LABORATORIES INCAug 7, 1996 to Feb 17, 19982

Timeline

  1. Sep 29, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed49
  2. Aug 11, 20268-K Results of operations50
  3. Aug 11, 20268-K Executive or director change51
  4. Jun 30, 20268-K Executive or director change52
  5. Jun 16, 20268-K Executive or director change; Shareholder vote53
  6. Jun 4, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares54
  7. May 12, 20268-K Results of operations55
  8. May 4, 20268-K Executive or director change56
  9. Mar 31, 20268-K Results of operations57
  10. Mar 23, 20268-K Other events58
  11. Feb 5, 20268-K Executive or director change59
  12. Jan 7, 20268-K Executive or director change60
  13. May 14, 2024New chief executive Stacy Lindborg becomes CEO14
  14. Jul 20, 2022New chief executive Goff Corinne Le becomes CEO15
  15. Jan 3, 2007New chief executive Michael H. Tardugno becomes CEO16
  16. Mar 16, 2006New chief executive Lawrence S. Olanoff becomes CEO17

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.16) a share, on Nov 13, 2025.61

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results50
  2. May 12, 2026Reported quarterly or annual results55
  3. Mar 31, 2026Reported quarterly or annual results57
  4. Nov 13, 2025Reported quarterly or annual results62
  5. Aug 5, 2025Reported quarterly or annual results63
  6. May 12, 2025Reported quarterly or annual results64
  7. Feb 27, 2025Reported quarterly or annual results65
  8. Nov 7, 2024Reported quarterly or annual results66

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

323 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 79 major events, 152 insider forms, 12 large holders, 2 private raises, 58 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Oct 13, 20264 EDGAR
  3. Oct 13, 20264 EDGAR
  4. Sep 29, 20268-K EDGAR
  5. Sep 28, 20264 EDGAR
  6. Sep 28, 20264 EDGAR
  7. Sep 28, 20264 EDGAR
  8. Sep 15, 20264 EDGAR
  9. Sep 15, 20264 EDGAR
  10. Sep 15, 20264 EDGAR
  11. Sep 1, 20264 EDGAR
  12. Sep 1, 20264 EDGAR
  13. Sep 1, 20264 EDGAR
  14. Sep 1, 20264 EDGAR
  15. Aug 17, 20264 EDGAR
  16. Aug 17, 20264 EDGAR
  17. Aug 17, 20264 EDGAR
  18. Aug 17, 20264 EDGAR
  19. Aug 14, 2026SCHEDULE 13G/A EDGAR
  20. Aug 11, 20268-K EDGAR

The 323 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 7 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 31, 2026Eylward SusanGeneral Counsel and Corp SecSale2,525$1.56$3.9KForm 4
Aug 17, 2026Eylward SusanGeneral Counsel and Corp SecSale2,449$1.63$4.0KForm 4
Aug 3, 2026Eylward SusanGeneral Counsel and Corp SecSale2,541$1.57$4.0KForm 4
Jul 20, 2026Eylward SusanGeneral Counsel and Corp SecSale2,150$1.78$3.8KForm 4
Jul 6, 2026Eylward SusanGeneral Counsel and Corp SecSale920$1.88$1.7KForm 4
Jun 29, 2026Eylward SusanGeneral Counsel and Corp SecSale11,800$1.75$20.6KForm 4
Aug 20, 2024Braun Donald PDirectorBuy25,000$1.18$29.5KForm 4
Aug 15, 2024Lindborg StacyPresident and CEOBuy25,000$0.98$24.5KForm 4
Aug 15, 2024Tardugno Michael HExecutive Chairman of BoardBuy25,000$1.03$25.8KForm 4
Apr 12, 2022Tardugno Michael HExecutive Chairman of BoardBuy4,000$3.53$14.1KForm 4
Apr 8, 2022Fritz Frederick J.DirectorBuy5,000$4.05$20.2KForm 4
Mar 2, 2022Fritz Frederick J.DirectorBuy2,000$4.69$9.4KForm 4
Oct 7, 2021Fritz Frederick J.DirectorBuy20,000$0.88$17.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Stacy Lindborg$568.1K$1.0M72
2025Michael Tardugno75$350.7K$605.9K72
2025Douglas FallerMD73$387.7K$589.8K72
2024President & CEO$342.0K$1.2M72
2024Executive Chairman & former interim CEO$336.6K$734.8K72

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 27, 2025Raised $3.3 million in a private offering of equity Form D: 3 investors so far Form D
  2. Aug 1, 2024Raised $10 million in a private offering of equity Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Armistice Capital, LLC144,767$257.7K0.0%−203,563
Riverview Capital Advisers, LLC34,364$247.8K0.1%No change
Vanguard Capital Management LLC46,967$83.6K0.0%−1,089
Geode Capital Management, LLC31,629$56.3K0.0%−1,582
Vanguard Fiduciary Trust Co13,269$23.6K0.0%No change
Northern Trust Corp10,342$18.4K0.0%New
UBS Group AG5,203$9.3K0.0%+4,628
BlackRock, Inc.4,464$7.9K0.0%No change
Tower Research Capital LLC (TRC)3,952$7.0K0.0%+2,086
Wells Fargo & Company/mn3,342$5.9K0.0%No change
Morgan Stanley1,574$2.8K0.0%−1,461
SBI Securities Co., Ltd.1,027$1.8K0.0%No change
Barclays PLC194$3450.0%New
Jpmorgan Chase & Co134$2410.0%New
Virtu Financial LLC17,456$310.0%New
Caitong International Asset Management Co., Ltd8$140.0%New
Group One Trading LLC6$110.0%No change
Northwestern Mutual Wealth Management Co3$50.0%New
Osaic Holdings, Inc.2$30.0%No change
Fmr LLC1$20.0%No change
Steigerwald, Gordon & Koch Inc.1$20.0%No change
Game Plan Financial Advisors, LLC1$20.0%No change
Royal Bank Of Canada1$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Imunon, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARImunon, Inc.1
  • CIK0000749647
  • Employer ID (EIN)52-12566154
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated indelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address997 Lenox Drive, Suite 100, Lawrenceville, NJ 086481
  • Phone(609) 896-91001
  • Shares outstanding5,611,403 as of Aug 10, 202611
  • Public float$21.2M as of Jun 30, 20254
  • AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 7, 19961
  • Filings1,462 in all: 4 (540), 8-K (336), 10-Q (91), 424B5 (36), 3 (35), CORRESP (31), 10-K (30), DEF 14A (30)1
    All 50 form types

    SC 13G/A (30), UPLOAD (26), 424B3 (25), EFFECT (24), SC 13G (24), S-1/A (22), S-3 (18), PRE 14A (16), S-8 (16), S-1 (15), DEFA14A (12), 10-K/A (9), 10-Q/A (9), 4/A (9), S-3/A (9), REGDEX (7), ARS (6), CT ORDER (6), D (6), 8-K/A (5), RW (5), SCHEDULE 13G/A (5), NT 10-Q (3), SC 13D/A (3), 8-A12B/A (2), CERTNAS (2), PRER14A (2), SC 13D (2), SCHEDULE 13G (2), 25 (1), 424B4 (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), DEFR14A (1), DRS (1), FWP (1), NT 10-K (1), POS AM (1), REGDEX/A (1), S-3MEF (1), S-8 POS (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) May 4, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, Par Value $0.01 Per ShareIMNNNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Imunon, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 36 risks under these headings, as written.4

  • Risk Related to Our Business and Operations
  • Risks Related to Intellectual Property
  • Risks Related to Our Securities
  • RISKS RELATED TO OUR BUSINESS AND OPERATIONS
  • We have a history of significant losses from operations and expect to continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability.
  • We might not be able to continue as a going concern, which could cause our stockholders to lose most or all of their investment.
  • We will need to raise additional capital to fund our planned future operations, and we may be unable to secure such capital without significant dilutive financing transactions. If we are not able to raise additional capital, we may not be able to complete the development, testing, and commercialization of our drug candidates.
  • If we do not obtain or maintain FDA and foreign regulatory approvals for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, we will be unable to sell those products and our business, results of operations and financial condition will be negatively affected.
  • Drug development is an inherently uncertain process with a high risk of failure at every stage of development.
  • New gene-based products for therapeutic applications are subject to extensive regulation by the FDA and comparable agencies in other countries. The precise regulatory requirements with which we will have to comply, now and in the future, are uncertain due to the novelty of the gene-based products we are developing.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • We rely on third parties to conduct all of our clinical trials. If these third parties are unable to carry out their contractual duties in a manner that is consistent with our expectations, comply with budgets and other financial obligations or meet expected deadlines, we may not receive certain development milestone payments or be able to obtain regulatory approval for or commercialize our drug candidates in a timely or cost-effective manner.
The other 28 risks
  • Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
  • If we fail to enter into and maintain successful strategic alliances for our drug candidates, we may have to reduce or delay our drug candidate development or increase our expenditures. To the extent we are able to enter into strategic transactions, we will be exposed to risks related to those collaborations and alliances.
  • We may not successfully engage in future strategic transactions, which could adversely affect our ability to develop and commercialize drug candidates, impact our cash position, increase our expenses and present significant distractions to our management.
  • We have obtained Orphan Drug Designation for IMNN-001 and may seek Orphan Drug Designation for other drug candidates, but we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.
  • Fast Track designation may not actually lead to a faster development or regulatory review or approval process.
  • Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable false claims act, anti-kickback, transparency, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, administrative burdens, reputational harm and diminished profits and future earnings.
  • Ongoing legislative and regulatory changes affecting the healthcare industry could have a material adverse effect on our business.
  • We may fail to comply with evolving European and other privacy and data protection laws, which could materially adversely affect our business.
  • The success of our products, if approved, may be harmed if the government, private health insurers and other third-party payers do not provide sufficient coverage or reimbursement.
  • Our products, if approved, may not achieve sufficient acceptance by the medical community to sustain our business.
  • We have no internal sales or marketing capability. If we are unable to create sales, marketing and distribution capabilities or enter into alliances with others possessing such capabilities to perform these functions, we will not be able to commercialize our products, if approved, successfully.
  • Our success will depend in part on our ability to grow and diversify, which in turn will require that we manage and control our growth effectively.
  • We face intense competition and the failure to compete effectively could adversely affect our ability to develop and market our products, if approved.
  • We may be subject to significant product liability claims and litigation.
  • Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
  • Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • Litigation and other legal proceedings against the Company, which may arise in the ordinary course of Company’s business, could be costly and time consuming to defend.
  • RISKS RELATED TO OUR INTELLECTUAL PROPERTY
  • Our business depends on license agreements with third parties to permit us to use patented technologies. The loss of any of our rights under these agreements could impair our ability to develop and market our products, if approved.
  • If any of our pending patent applications are not issued, or are deemed invalid following issuance, or if our issued patents expire without obtaining issuance of our later-filed patent applications, we may lose valuable intellectual property protection.
  • We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
  • RISKS RELATED TO OUR SECURITIES
  • The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors and subject us to securities class action litigation.
  • We may be unable to maintain compliance with The Nasdaq Marketplace Rules, which could cause our common stock to be delisted from the Nasdaq Capital Market. This could result in the lack of a market for our common stock, cause a decrease in the value of an investment in us, and adversely affect our business, financial condition, and results of operations.
  • Future sales of our common stock in the public market could cause our stock price to fall.
  • Our stockholders may experience significant dilution as a result of future equity offerings or issuances and exercise of outstanding options and warrants.
  • Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and share price.
  • We have never paid cash dividends on our common stock in the past and do not anticipate paying cash dividends on our common stock in the foreseeable future.
  • Anti-takeover provisions in our charter documents and Delaware law could prevent or delay a change in control.

Legal proceedings

We are not currently a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72